Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
33 Leser
Artikel bewerten:
(0)

DaVita Names Chief Medical Officer for Saudi Operations

-- Dr. Abdulkareem Alsuwaida joins DaVita team in Saudi Arabia

RIYADH, Saudi Arabia, June 22, 2014 /PRNewswire/ -- DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced it has named Dr. Abdulkareem Alsuwaida, FRCPC, MSc, as chief medical officer for its operations in the Kingdom of Saudi Arabia.

Video - http://youtu.be/miYpaBN7QEU
Photo - http://photos.prnewswire.com/prnh/20140618/119402
Logo - http://photos.prnewswire.com/prnh/20140318/DC85712LOGO

"Clinical excellence defines Dr. Alsuwaida's distinctive nephrology career," said Dennis Kogod, president of DaVita Kidney Care International. "He's devoted his professional life to improving the quality of care for chronic kidney disease (CKD) patients in the Kingdom of Saudi Arabia. This aligns wonderfully with DaVita's commitment to provide world-class, comprehensive care in our long-term partnership with the Kingdom's Ministry of Health. We're honored to have him on board."

Dr. Alsuwaida is currently a professor of medicine and director of postgraduate education at King Saud University in Riyadh. He is also a consultant in the Division of Nephrology at the King Khalid University Hospital. Dr. Alsuwaida earned a medical degree from King Abdulaziz University and completed postgraduate medical education in internal medicine and nephrology at the University of Toronto. Additionally, he earned a master's degree in clinical epidemiology from the University of Toronto. A past president of the Saudi Society of Nephrology, Dr. Alsuwaida's research is focused on dialysis, glumorelonephritis and lupus nephritis. He has published more than 40 papers on these topics.

"Providing world-class care is a top priority, not only for the Ministry of Health, but also for the thousands of Saudi men and women affected by CKD and their families," said Alsuwaida. "In the United States as well as in other countries, DaVita has played a significant role in elevating the standard of care. DaVita's presence in the Kingdom represents a long-term commitment to improving the overall health of Saudi citizens."

In February 2014, DaVita signed a major tender from the Kingdom of Saudi Arabia's Ministry of Health in which it will deliver care to 5,000 dialysis patients currently under the ministry's care.

"These patients will ultimately benefit from Dr. Alsuwaida joining the DaVita team in the Kingdom," said Abdulrahman Al Haidari, country manager for DaVita in Saudi Arabia.

DaVita and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita HealthCare Partners Inc.

About DaVita Kidney Care
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2014, DaVita Kidney Care operated or provided administrative services at 2,098 outpatient dialysis centers located in the United States serving approximately 165,000 patients. The company also operated 75 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.

Contact Information
Media:
David Tauchen
David.Tauchen@DaVita.com
+001-303-876-2802



© 2014 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.